TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03191682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL3-ZUMAB
Description: The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
Study: NCT01815944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5%
Study: NCT01045967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg delayed-release Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg delayed-release Capsule
Study: NCT01863381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic membrane displacement (TMD)
Description: The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPOAE
Description: DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
Study: NCT00675714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
Study: NCT02706899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Intravenous (IV) push every 4 weeks
Study: NCT03042117

Intervention type: OTHER
Intervention: periodontal probing
Description: A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects

Intervention type: OTHER
Intervention: periodontal probing
Description: A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects

Intervention type: OTHER
Intervention: periodontal probing
Description: A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
Study: NCT01879917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05118646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sublingual microcirculation,
Description: Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.

Intervention type: DEVICE
Group type: OTHER
Intervention: hemodynamic monitoring
Description: Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodynamic monitoring
Description: Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
Study: NCT03194906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
Study: NCT02040623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.2%
Description: R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.5%
Description: R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution 2 drops per eye twice a day
Study: NCT01403623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation and post resuscitation care with plastic bag
Description: Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
Study: NCT02706899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for 33A)
Description: Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
Study: NCT03435354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counselling
Description: Clinician counselling about physical activity using standardized tools to promote daily physical activity.
Study: NCT02274532

Intervention type: DEVICE
Group type: OTHER
Intervention: SoftHand
Description: Biomechanical, ADL, and functional testing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftHand
Description: Biomechanical, ADL, and functional testing.
Study: NCT01403623

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Resuscitation- no plastic bag for temperature regulation
Description: Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
Study: NCT06083649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AI-assisted tool used in this study was called Dental Monitoring (DM).
Description: DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AI-assisted tool used in this study was called Dental Monitoring (DM).
Description: DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
Study: NCT03342586

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting State fMRI (rsfMRI)
Description: rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).

Intervention type: OTHER
Intervention: Auditory Attention and Executive Functions Test
Description: * Trail Making Test (Parts A \& B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~* Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~* Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes.

Intervention type: OTHER
Intervention: Memory Test
Description: The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.

Intervention type: OTHER
Intervention: Motor Speed Test
Description: Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.

Intervention type: OTHER
Intervention: Self Reported Quality of Life Questionnaire
Description: The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
Study: NCT03250637

Intervention type: OTHER
Intervention: Observational
Description: Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews

Intervention type: OTHER
Intervention: Observational
Description: Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
Study: NCT01419769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS Stent & Delivery System
Description: The AXIOS Stent \& Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal.
Study: NCT03274323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent and travoprost or latanoprost
Description: 2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Standard trabeculectomy
Study: NCT01650298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug (Direct thrombin or Factor Xa inhibitor)
Description: Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
Study: NCT03656003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procore biopsy needle
Description: EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional biopsy needle
Description: EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
Study: NCT00443040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
Study: NCT00763412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
Study: NCT03622008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEP-TAZ 4 g
Description: FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV
Study: NCT01776658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: Ocular topical administration of SYL1001 for 10 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocular topical administration of placebo for 10 consecutive days
Study: NCT02321241

Intervention type: DRUG
Intervention: Aflibercept (EYLEA, BAY-86-5321)
Description: 1. st year: 3 monthly injections followed by 1 injection every two months~2. nd year and following: injection according the visual and anatomical results observed the 1st year
Study: NCT00475670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane (docetaxel or paclitaxel)
Description: Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
Study: NCT04128137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: 50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
Study: NCT02549547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Medical Visits
Description: Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~* Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~* Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~* Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity.
Study: NCT02870777

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MRD-directed therapy
Description: The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
Study: NCT03922581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
Study: NCT01473771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Letter (email)
Description: Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period.
Study: NCT00905450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303242-X
Description: Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for BOL-303242-X
Description: Medication instilled into the study eye, subjects randomized to various drug dose schedules.
Study: NCT03683173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
Study: NCT04258930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum sulphate and calcium acetate drying soaks
Description: Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical sterile silicone gel for wounds
Description: Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Description: Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).